TIDMAGL
Angle PLC
12 April 2019
For immediate release 12 April 2019
ANGLE plc ("the Company")
LUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
Leading ANGLE customer has established a multi-centre study
using Parsortix seeking to identify markers for early prediction of
cancer relapse in non small cell lung cancer
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce that a leading customer has
established a multi-centre study to investigate biomarkers on
circulating tumor cells (CTCs), using ANGLE's Parsortix(TM) system,
which may give advance warning of relapse in non small cell lung
cancer (NSCLC).
The study is being conducted by the Hellenic Oncology Research
Group ("Hellenic") lead by the Principal Investigators, Associate
Professor Athanasios Kotsakis and Professor Vassilis Georgoulias of
the IASO General Hospital in Athens, Greece and is investigating
both ctDNA (circulating tumor DNA, fragments of dead cancer cells)
and CTCs. The CTC evaluation is being undertaken by the University
of Athens lead by Professor Evi Lianidou. Parsortix is the only CTC
system being used in the study.
Lung cancer has the highest incidence and mortality rate of all
cancers (World Cancer Factsheet 2018: 2.1 million new cancer cases
and 1.8 million deaths per annum). Even where the cancer is
detected early, 45% of all NSCLC patients will suffer disease
recurrence within 8 to 18 months of surgery. Where the cancer is
detected late, the situation is far worse. Advance warning of
potential cancer relapse in NSCLC has the potential to improve
patient outcomes by allowing targeted treatment earlier than would
otherwise happen. Solid tissue biopsies are impractical on the
repeat basis needed for follow-up monitoring. Where they are
possible, the tissue biopsy is expensive, and carries significant
risk: up to 24% cause serious complications and up to 1% result in
death.
The Hellenic study involves 50 operable early stage NSCLC
patients having liquid biopsy blood tests prior to surgery, one
month after surgery and then every three to six months until
relapse. The study is scheduled to complete in December 2021. CTCs
harvested from patient blood using the Parsortix system will be
analysed using qRT-PCR and FISH to identify tumor clonal evolution
with the intention of identifying both predictors of relapse and
indications of suitable treatment.
Prof Evi Lianidou, Head of the Molecular Diagnostics Laboratory
focused on Liquid Biopsy, University of Athens, commented:
"Following our successful work in head and neck cancer with
ANGLE's Parsortix system, we are delighted to have initiated this
important longitudinal study in non small cell lung cancer (NSCLC).
There is a major unmet medical need in NSCLC to predict early
relapse and identify targeted therapies for personalised care. We
are excited about the potential for analysis of CTCs harvested by
the Parsortix system to make a real difference for these
patients."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"This is another example of ANGLE's product based leveraged
R&D approach delivering key benefits with a major study, which
is being developed, executed and funded by a leading customer. The
high incidence and mortality rates of lung cancer create a pressing
need for repeat biopsies to allow personalised medicine and we hope
that our Parsortix liquid biopsy system can play a key role in
delivering this to the benefit of patients, opening new markets for
ANGLE."
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Carl Holmes, Simon
Hicks, Max Bullen-Smith
ECM - Alice Lane +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig,
Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 212 850 5624
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
platforms include an epitope-independent circulating tumor cell
(CTC) harvesting technology and a downstream analysis system for
cost effective, highly multiplexed analysis of nucleic acids and
proteins.
ANGLE's cell separation technology is called the Parsortix(TM)
system, and it enables a liquid biopsy (a simple blood test) to be
used to provide the cells of interest to the user in a format
suitable for multiple downstream subsequent analyses. CTCs enable
the complete picture of a cancer to be seen as they allow DNA, RNA
and protein analysis and the live cells harvested can be cultured.
The Parsortix technology is the subject of 21 granted patents in
Europe, the United States, Canada, India, China, Japan and
Australia with three extensive families of patents are being
progressed worldwide. The system is based on a microfluidic device
that captures cells based on a combination of their size and
compressibility. The Parsortix system has a CE Mark in Europe for
the indicated use and FDA clearance is in process for the United
States with a 400 subject study in metastatic breast cancer. ANGLE
is seeking to be the first ever FDA cleared CTC harvesting system
and only the third ever FDA cleared liquid biopsy test. ANGLE has
already undertaken two separate 200 subject clinical studies under
a program designed to develop an ovarian cancer pelvic mass triage
test, with the results showing best in class accuracy (ROC-AUC) of
95.1%. The pelvic mass triage assay has undergone further
refinement and optimisation, and is currently in the process of a
clinical verification study.
ANGLE's technology for the multiplex evaluation of proteins and
nucleic acids of all types is called the HyCEAD(TM) Ziplex(R)
platform and is based on a patented flow through array technology.
It provides for low cost, highly multiplexed, rapid and sensitive
capture of targets from a wide variety of sample types. A
proprietary chemistry approach (the HyCEAD method) allows for the
capture and amplification of over 100 biomarkers simultaneously in
a single reaction. The HyCEAD Ziplex system is ideal for measuring
gene expression and other markers directly from Parsortix harvests
and was used in the ovarian cancer pelvic mass triage test to
achieve best in class accuracy (ROC-AUC) of 95.1%.
ANGLE's proprietary technologies can be combined to provide
automated, sample-to-answer results in both centralised laboratory
and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as QIAGEN, Abbott and
Philips, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
18 peer-reviewed publications and numerous publicly available
posters, available on our website.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAZMGMDLMKGLZM
(END) Dow Jones Newswires
April 12, 2019 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024